Is Zyne (Zyne) stock a good value?
Apr 14, 2022 · Zynerba Pharmaceuticals Stock Forecast, Price & News $1.78 +0.03 (+1.71%) (As of 04/13/2022 04:00 PM ET) Today's Range $1.75 $1.82 50-Day Range $1.75 $2.89 52-Week Range $1.73 $6.07 Volume 134,041 shs Average Volume 415,501 shs Market Capitalization $75.56 million P/E Ratio N/A Dividend Yield N/A Beta 2.11 Profile Analyst Ratings Chart
What is the 12-month stock price forecast for zynerba Pharmaceuticals Inc (Zyne)?
Apr 08, 2022 · Real-time trade and investing ideas on Zynerba Pharmaceuticals ZYNE from the largest community of traders and investors.
What are analysts'price targets for zynerba Pharmaceuticals'stock?
Apr 04, 2022 · Analyst Forecast. According to 12 analysts, the average rating for ZYNE stock is "Buy." The 12-month stock price forecast is 7.09, which is …
Is zynerba pharmaceuticals (Zyne) oversold?
ZYNE | Complete Zynerba Pharmaceuticals Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.
Is ZYNE a good stock to invest?
Out of 4 analysts, 3 (75%) are recommending ZYNE as a Strong Buy, 0 (0%) are recommending ZYNE as a Buy, 1 (25%) are recommending ZYNE as a Hold, 0 (0%) are recommending ZYNE as a Sell, and 0 (0%) are recommending ZYNE as a Strong Sell. What is ZYNE's earnings growth forecast for 2022-2024?
What does ZYNE pharmaceuticals make?
About Zynerba Pharmaceuticals Inc Zynerba Pharmaceuticals, Inc. is primarily engaged in the pharmaceutically produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, including Fragile X syndrome (FXS), autism spectrum disorder (ASD), and 22q11. 2 deletion syndrome (22q).
Will ZYNE stock go up?
Stock Price Forecast The 4 analysts offering 12-month price forecasts for Zynerba Pharmaceuticals Inc have a median target of 7.00, with a high estimate of 9.00 and a low estimate of 2.75. The median estimate represents a +332.10% increase from the last price of 1.62.
What is Zynerba pharmaceuticals?
Zynerba Pharmaceuticals, Inc. engages in the provision of pharmaceutically-produced transdermal cannabinoid therapies. It focuses on the research and development of rare and near-rare neuropsychiatric conditions.
Where is Zynerba Pharmaceuticals located?
Devon, PennsylvaniaZynerba Pharmaceuticals is located in Devon, Pennsylvania, United States .
Is Zynerba Pharmaceuticals a buy right now?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zynerba Pharmaceuticals in the last twelve months. There are currently 3 b...
How has Zynerba Pharmaceuticals' stock been impacted by COVID-19?
Zynerba Pharmaceuticals' stock was trading at $3.89 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organiz...
Are investors shorting Zynerba Pharmaceuticals?
Zynerba Pharmaceuticals saw a decline in short interest in the month of January. As of January 31st, there was short interest totaling 2,090,000 sh...
When is Zynerba Pharmaceuticals' next earnings date?
Zynerba Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, May 11th 2022. View our earnings forecast f...
How were Zynerba Pharmaceuticals' earnings last quarter?
Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) announced its quarterly earnings results on Tuesday, March, 1st. The company reported ($0.22) earnings...
What price target have analysts set for ZYNE?
3 Wall Street analysts have issued 1 year price objectives for Zynerba Pharmaceuticals' stock. Their forecasts range from $8.00 to $9.00. On averag...
Who are Zynerba Pharmaceuticals' key executives?
Zynerba Pharmaceuticals' management team includes the following people: Armando Anido , Chairman & Chief Executive Officer Terri B. Sebree , Pre...
Who are some of Zynerba Pharmaceuticals' key competitors?
Some companies that are related to Zynerba Pharmaceuticals include Nature's Sunshine Products (NATR) , Oramed Pharmaceuticals (ORMP) , VBI Vacci...
What other stocks do shareholders of Zynerba Pharmaceuticals own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Zynerba Pharmaceuticals investors own include (CGC) , Ca...
About Zynerba Pharmaceuticals
Headlines
Zynerba Pharmaceuticals, Inc. engages in the provision of pharmaceutically-produced transdermal cannabinoid therapies. It focuses on research and development of rare and near-rare neuropsychiatric conditions. The firm offers Zygel product, which formulated as a permeation-enhanced gel for transdermal delivery. The company was founded by Audra L.
About ZYNE
Zynerba announces clinical updates for Fragile X and 22q11.2...Zynerba announces clinical updates for Fragile X and 22q11.2...
Analyst Forecast
Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. It focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders.
News
According to 12 analysts, the average rating for ZYNE stock is "Buy." The 12-month stock price forecast is 7.24, which is an increase of 208.09% from the latest price.
Signals & Forecast
Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) has appointed Albert P. Parker, an accomplished industry executive with over 25 years of pharmaceutical, biotech and healthcare experience, as chief legal off...
Support, Risk & Stop-loss
A buy signal was issued from a pivot bottom point on Friday, January 21, 2022, and so far it has risen 4.64%. Further rise is indicated until a new top pivot has been found. Furthermore, there is a buy signal from the 3 month Moving Average Convergence Divergence (MACD).
Is Zynerba Pharmaceuticals stock A Buy?
Zynerba Pharmaceuticals finds support from accumulated volume at $2.45 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.
Insiders are very negative
Zynerba Pharmaceuticals holds several negative signals and is within a very wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock.
About Zynerba Pharmaceuticals
In the last 1 trades there were . The last trade was done 19 046 days ago by who bough 0 shares.
Golden Star Signal
Zynerba Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing proprietary synthetic cannabinoid therapeutics formulated for transdermal delivery.
Top Fintech Company
This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star. This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!
Historical and forecast chart of Zynerba stock
featured in The Global Fintech Index 2020 as the top Fintech company of the country.
Zynerba Daily Price Targets
The chart below shows the historical price of Zynerba stock and a prediction chart for the next month. For convenience, prices are divided by color. Forecast prices include: Optimistic Forecast, Pessimistic Forecast, and Weighted Average Best Forecast. Detailed values for the Zynerba stock price can be found in the table below.
Zynerba forecast for this year
Forecast target price for 02-26-2022: $ 2.18. Negative dynamics for Zynerba shares will prevail with possible volatility of 6.449%.
Zynerba information and performance
An uptrend is forecast for this month with an optimal target price of $ 2.40075. Pessimistic: $2.06. Optimistic: $2.73
